An automated electrophysiological assay for differentiating Ca V2.2 inhibitors based on state dependence and kinetics

Assay and Drug Development Technologies

Volumn 10, Issue 6, 2012, Pages 542-550

  Swensen, Andrew M ^a   Niforatos, Wende ^a   Vortherms, Timothy A ^a   Perner, Richard J ^a   Li, Tao ^a   Schrimpf, Michael R ^a   Scott, Victoria E ^a   Lee, Lance ^a   Jarvis, Michael F ^a   McGaraughty, Steve ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL N TYPE; OMEGA CONOTOXIN MVIIA;

ANIMAL CELL; ARTICLE; AUTOMATION; BINDING KINETICS; CONTROLLED STUDY; DEPOLARIZATION; ELECTROPHYSIOLOGY; METHODOLOGY; NONHUMAN; RAT;

ANIMALS; AUTOMATION; BIOLOGICAL ASSAY; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; CELL LINE; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; INDOLES; KINETICS; OMEGA-CONOTOXINS; PATCH-CLAMP TECHNIQUES; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TRIAZOLES;

EID: 84870865572     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2011.437     Document Type: Article

References (26)

1. Catterall WA: Structure and regulation of voltage-gated Ca2 + channels. Annu Rev Cell Dev Biol 2000;16:521-555.
2. Evans AR, Nicol GD, Vasko MR: Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res 1996;712:265-273.
3. Gohil K, Bell JR, Ramachandran J, Miljanich GP: Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 1994;653:258-266.
4. Westenbroek RE, Hoskins L, Catterall WA: Localization of Ca2 + channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 1998;18:6319-6330.
5. Saegusa H, Matsuda Y, Tanabe T: Effects of ablation of N- and R-type Ca(2 +) channels on pain transmission. Neurosci Res 2002;43:1-7.
6. Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR: Selective Ntype neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996;279:1243-1249.
7. Miljanich GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004;11:3029-3040.
8. Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S: Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 2000;84:151-158.
9. Staats PS, Yearwood T, Charapata SG, et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291:63-70.
10. Yamamoto T, Takahara A: Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 2009;9:377-395.
11. Feng ZP, Doering CJ, Winkfein RJ, Beedle AM, Spafford JD, Zamponi GW: Determinants of inhibition of transiently expressed voltage-gated calciumchannels by omega-conotoxins GVIA and MVIIA. J Biol Chem 2003;278:20171-20178.
12. Stocker JW, Nadasdi L, Aldrich RW, Tsien RW: Preferential interaction of omegaconotoxins with inactivated N-type Ca2 + channels. J Neurosci 1997;17:3002- 3013.
13. Snutch TP: Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005;2:662-670.
14. Winquist RJ, Pan JQ, Gribkoff VK: Use-dependent blockade of Cav2.2 voltagegated calcium channels for neuropathic pain. Biochem Pharmacol 2005;70:489-499.
15. Abbadie C, McManus OB, Sun SY, et al.: Analgesic effects of a substituted Ntriazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther 2010;334:545-555.
16. Benjamin ER, Pruthi F, Olanrewaju S, et al.: Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR. Biochem Pharmacol 2006;72:770-782.
17. Finley MF, Lubin ML, Neeper MP, et al.: An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists. Assay Drug Dev Technol 2010;8:685-694.
18. Lubin ML, Reitz TL, Todd MJ, Flores CM, Qin N, Xin H: A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye. Assay Drug Dev Technol 2006;4:689-694.
19. Zhang SP, Kauffman J, Yagel SK, Codd EE: High-throughput screening for Ntype calcium channel blockers using a scintillation proximity assay. J Biomol Screen 2006;11:672-677.
20. Dai G, Haedo RJ, Warren VA, et al.: A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol 2008;6:195-212.
21. Vortherms TA, Swensen AM, Niforatos W, et al.: Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels. Inflamm Res 2011;60:683-693.
22. Dubin AE, Nasser N, Rohrbacher J, et al.: Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 2005;10:168-181.
23. Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T: Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 2005;3:47-57.
24. Errington AC, Stohr T, Heers C, Lees G: The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-169.
25. Hildebrand ME, Smith PL, Bladen C, et al.: A novel slow-inactivation- specific ion channel modulator attenuates neuropathic pain. Pain 2011;152:833-843.
26. Jo S, Bean BP: Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol Pharmacol 2011;80:247-257.